<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2D08B3B4-46BE-467D-8644-AEF99777FE88"><gtr:id>2D08B3B4-46BE-467D-8644-AEF99777FE88</gtr:id><gtr:name>Los Angeles Institute of Allergy and Clinical Immunology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/64300AF7-F2A5-4EEC-983A-CC4168C9C664"><gtr:id>64300AF7-F2A5-4EEC-983A-CC4168C9C664</gtr:id><gtr:name>Virginia Commonwealth University</gtr:name><gtr:address><gtr:line1>Virginia Commonwealth University</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/150CE820-6372-414E-9F7F-524E27034E23"><gtr:id>150CE820-6372-414E-9F7F-524E27034E23</gtr:id><gtr:name>University of Colorado at Boulder</gtr:name><gtr:address><gtr:line1>Boulder</gtr:line1><gtr:line4>Colorado</gtr:line4><gtr:line5>80309-0425</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Randall Div of Cell and Molecular Biophy</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2D08B3B4-46BE-467D-8644-AEF99777FE88"><gtr:id>2D08B3B4-46BE-467D-8644-AEF99777FE88</gtr:id><gtr:name>Los Angeles Institute of Allergy and Clinical Immunology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/64300AF7-F2A5-4EEC-983A-CC4168C9C664"><gtr:id>64300AF7-F2A5-4EEC-983A-CC4168C9C664</gtr:id><gtr:name>Virginia Commonwealth University</gtr:name><gtr:address><gtr:line1>Virginia Commonwealth University</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/150CE820-6372-414E-9F7F-524E27034E23"><gtr:id>150CE820-6372-414E-9F7F-524E27034E23</gtr:id><gtr:name>University of Colorado at Boulder</gtr:name><gtr:address><gtr:line1>Boulder</gtr:line1><gtr:line4>Colorado</gtr:line4><gtr:line5>80309-0425</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B8DE35C1-BD77-40C7-A617-698BD33A5AB7"><gtr:id>B8DE35C1-BD77-40C7-A617-698BD33A5AB7</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Sutton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/80CC8B4C-7103-471D-AB94-884EF0AAFBB9"><gtr:id>80CC8B4C-7103-471D-AB94-884EF0AAFBB9</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>McDonnell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C68DCAD6-AB77-43CC-AEAF-45EB93348FA8"><gtr:id>C68DCAD6-AB77-43CC-AEAF-45EB93348FA8</gtr:id><gtr:firstName>Hannah</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Gould</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0200486"><gtr:id>0A2A94C4-7443-4CBC-988C-9565B3840A6F</gtr:id><gtr:title>Structural studies of protein-protein interactions of the IgE network</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200486</gtr:grantReference><gtr:abstractText>The incidence of allergic disease in the UK is already high and is increasing. There is an urgent need for new therapies, and the long-term aim of this project is to further the development of new therapeutic compounds. Antibodies of a type known as immunoglobulin E (IgE) are crucially involved in the allergic response, and individuals susceptible to allergies have high levels of IgE in the blood. The IgE antibodies are the link between the allergens that enter the airways (such as grass pollen and house dust mites), the gut (food allergens) or the skin (contact allergies), and the body?s cells that trigger the allergic reaction. These are called mast cells, and the IgE antibodies bind to them through molecules on the cell surface known as ?receptors?. If we can block the binding of the IgE antibodies to the receptors, then all of these manifestations of allergic disease would be prevented.

In order to design compounds that will block this step in the allergic reaction, we need to know the detailed molecular structures of IgE and the receptor. We use both X-ray and magnetic resonance imaging techniques applied to individual molecules, to work out their atomic structures. Using these same techniques, we can also study the way in which the molecules bind to each other. In this way we shall build up an understanding at the molecular level of how the allergic response works. We also plan to study the molecular interactions that control the levels of IgE production in the body, and we have already set up experimental systems using nasal and lung biopsy material from patients with allergic rhinitis and asthma, to test the effects of potential inhibitors.

This programme of work provides the starting point for the design of compounds to inhibit these interactions. Such compounds are potential therapeutic agents for the treatment of allergic disorders.</gtr:abstractText><gtr:technicalSummary>Allergic disease now affects one person in six in the UK, and the incidence of certain conditions such as childhood asthma is increasing. Interactions between immunoglobulin E (IgE) and its receptors are crucially involved at various stages of the allergic response, including the presentation of allergens to the immune system, the regulation of IgE synthesis and perhaps also the switch to IgE production by B cells, and the triggering of mast cells and basophils in the immediate hypersensitivity reaction. We have embarked upon a programme of structural studies of these proteins and their complexes - IgE and IgE Fc, FceRI (the high affinity mast cell receptor), FceRII/CD23 (the low affinity B cell receptor), CR2/CD21 (the counter-receptor for CD23 on B cells) - by X-ray crystallography, NMR and other biophysical techniques. Understanding the molecular details of these interactions, all of which are potential points of therapeutic intervention, is essential for the design and/or screening for blocking agents. We have recently determined the crystal structure of the complete IgE Fc [1], and shown by NMR that the Ce2 domains of IgE interact with FceRI [2]; studies of CD23 by both X-ray crystallography and NMR are in progress. Future structural studies of their complexes require the production of large amounts of many different soluble versions of these various proteins. Site-specific mutant versions of these proteins will also be produced for NMR and BIAcore experiments to investigate the kinetics of the interactions and the role of key residues. These protein fragments are themselves potential inhibitors, and will be tested in functional assays for IgE synthesis and allergen presentation. These assays have been developed through collaborations within the Co-operative Group: for IgE synthesis, between HJG and Prof. Stephen Durham and Dr. Chris Corrigan, and for allergen presentation, between HJG and Dr. Catherine Hawrylowicz (the latter two in Prof. Tak Lee?s Department). 

This application is for technical assistance to support these structural and functional studies, through the expression of the various recombinant proteins in different systems (mammalian, yeast, bacterial), their purification, characterisation and crystallisation. This support will underpin the collaboration between the three applicants, together with four other members of the Co-operative Group. The scientific aims of this project are central to the long-term goals of the Group, namely the development of therapeutic agents for intervention in allergic disease.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>241040</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Virginia Commonwealth University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Professor Dan Conrad</gtr:description><gtr:id>9AE25FAF-F286-4E88-89CD-036057D6FF10</gtr:id><gtr:impact>Publications; undertanding of the role of CD23 in IgE regulation and production in B cells.</gtr:impact><gtr:partnerContribution>Expertise in functional assays for role of CD23 in IgE synthesis</gtr:partnerContribution><gtr:piContribution>Provision materials, carrying out experimental work, biophysical characterisation etc.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Novartis</gtr:description><gtr:id>66B5BBBB-BF37-4367-A3F8-1A7C72B152CE</gtr:id><gtr:impact>A clinical trial has been initiated as a result of the collaboration; additional funding was obtained from other sources; understanding of role of IgE in non-atopic asthma</gtr:impact><gtr:partnerContribution>Provision of anti-IgE and manpower to conduct the experiments</gtr:partnerContribution><gtr:piContribution>Expertise in IgE and clinical trial facilities and patients.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Los Angeles Institute of Allergy and Clinical Immunology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Professor Toshi Kawakami</gtr:description><gtr:id>4605D1F0-32D0-4BDD-B7C8-4DFA75AD7B90</gtr:id><gtr:impact>Demonstration that human IgE can exert cytokinergic activity; this has profound implications for the pathogenesis of allergic disease and asthma in particular.</gtr:impact><gtr:partnerContribution>Expertise in analysis of cytokinergic IgE; sequence data.</gtr:partnerContribution><gtr:piContribution>Provision of cDNA of potentially cytokinergic IgE for analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>Professor Erika Jensen-Jarolim</gtr:description><gtr:id>2FCAF3D4-FED7-4750-B422-ED35F7F2CD67</gtr:id><gtr:impact>Several publications; further funding from BRC and CRUK; a clinical trial of a monoclonal IgE (in progress); studentships from BRC.</gtr:impact><gtr:partnerContribution>Two students from the Vienna lab worked at King's on functional studies of chimeric monoclonal IgEs against ovarian cancer.</gtr:partnerContribution><gtr:piContribution>Expertise in IgE function; recombinant DNA technology; materials and facilities for the functional studies, all of which were performed at King's.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Colorado</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Colorado (Denver)</gtr:department><gtr:description>Professor Michael Holers</gtr:description><gtr:id>53542614-BA7F-4408-8950-3955939BF1E2</gtr:id><gtr:impact>Publications (see list); understanding the role of CD23 and complement receptor (CD21) interactions in autoimmune disease, and allergy.</gtr:impact><gtr:partnerContribution>Provision of materals.</gtr:partnerContribution><gtr:piContribution>Provision of CD23 and other reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Dr. David Dombrowicz</gtr:description><gtr:id>9726D0F3-DEEC-4083-9DD0-983104DDD64C</gtr:id><gtr:impact>Publications; proof of concept for inhibition of IgE/FceRI for treatment of allergy, and also for monoclonal antibodies in immunotherapy of cancer; development of an animal models.</gtr:impact><gtr:partnerContribution>Transgenic mouse model of allergy and cancer.</gtr:partnerContribution><gtr:piContribution>Material and labour and expertise in IgE, CD23 and FceRI.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentations at Asthma UK events</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>51AE8467-9F3F-4C3B-A004-20406F26AAE0</gtr:id><gtr:impact>Presented my research on IgE and the development of novel therapeutics to fundraisers, supporters and patients at events organised by Asthma UK.

Raises profile of asthma research nationally. Assisted the charity in attracting new donors and raising funds for asthma research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper and radio interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>98F3543A-C62C-4859-85F0-8BE64C0E76D7</gtr:id><gtr:impact>Articles and interviews concerning the trials of IgE in the immunotherapy of cancer

Raised awareness of this approach with the public and assisted in gaining funding.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminars on development of IgE inhibitors</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3F1B5D11-AA22-46B5-B9D3-E5667958B12F</gtr:id><gtr:impact>Various talks to companies, under confidentiality agreements (UCB Celltech, UK; AstraZeneca, Sweden; Pfizer, UK &amp;amp; USA)

We successfully negotiated an agreement with a company for collaborative development of IgE inhibitors.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Asthma UK Website for World Asthma Day</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>548008B5-E8F4-4CDE-A2A9-B68B8D917DB2</gtr:id><gtr:impact>Report of our asthma research to develop a novel therapy was highlighted on the website and in publicity material distributed in association with World Asthma Day, 2009.

Raised profile of the need for more research funding and clinical provision for asthma.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sixth Form talks on Asthma, Allergy and Drug Design</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>57E46131-EE31-4741-8B74-DF91E80488B3</gtr:id><gtr:impact>Talks to Sixth Forms, most recently at Magdalen College School, Oxford, and St. Paul's School, London.

Very positive feedback from school staff about pupils' future subject choices at university and career plans. Led to collaborative project with St. Paul's School sixth form; students spend day in lab at King's.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Telephone interviews with journalists</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3C2DA990-3E15-447A-9A46-A74007DB3CA2</gtr:id><gtr:impact>Telephone interviews with journalists about our IgE work and development of new drugs. Press releases accompanied recent publication in J. Biol. Chem. Reports in the Times, Daily Telegraph, Daily Mail, London Metro, NHS Web pages.

Raises profile of our work nationally, and of the need for research into allergy and asthma generally.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sixth Form talks on Asthma, Allergy and Drug Design</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3C17F116-93DF-4021-9281-E7E960BA9E8C</gtr:id><gtr:impact>Most recently to St. Paul's School, London.

Positive feedback from teachers about pupils' university choices and career plans. This talk led to initiation of a project to bring sixth formers into King's to carry out an experiemtnal project involving molecular and structural biology. First run in 2009, the scheme was a great success and will be repeated annually.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar on novel asthma/allergy therapy development</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0771B506-7FF9-433C-86DE-541A4B478432</gtr:id><gtr:impact>Presented at several activities organised by Asthma UK aimed at their fundraisers, other supporters and of course including patients.

Raied profiule for our work, and the role of structural biology in the drug discovery process. Enhanced the ability of the charity to engage new donors and raise funds for asthma research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 Programme</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D03A0D75-E263-4BE4-987C-17476C2C075F</gtr:id><gtr:impact>Contributed to a BBC Radio Programme on Asthma provision and asthma research: Our Lives in Our Hands - Asthma, Living on a Knife Edge.

Raised profile of the life-threatening aspect of asthma and allergic disease, and of the widespread nature of asthma.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Telephone interviews with newspapers</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D259FB3C-EE6C-4D24-9AB0-899D3B7C3A97</gtr:id><gtr:impact>Various interviews leading to pieices in newspapers: Times, Daily Telegraph, Sunday Times, Daily Mail, London Metro, NHS Web pages. (Earlier years: breakfast TV appearance and Radio 4 programme &amp;quot;Leading Edge&amp;quot;)

Raised national public profile of allergy research generally.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminars on development of IgE inhibitors for anti-allergy therapy</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AFECD478-A299-41FB-8D30-6266B4164AE3</gtr:id><gtr:impact>Discussions under confidentiality agreements, with various companies, recently UCB-Celltech (UK), AstraZeneca (Sweden) and Pfizer (UK and USA).

Negotiations concluded with one UK-based company; unable to provide further details at present.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper and radio interviews</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>13F54878-3A97-4428-818A-EDDC4569E840</gtr:id><gtr:impact>Articles and interviews concerning the trials of IgE in the immunotherapy of cancer

Raised awareness of this approach with the public and assisted in gaining funding.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>261554</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St. Thomas's Trust Charity, Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:id>D2C76E7F-4835-4F99-A615-03237240E6D8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St. Thomas' Charity/Novartis Clinical Trial</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:id>1E33DE53-DCB6-4B88-B9D6-6F47488480AB</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Project Grant</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>3990C968-50C5-45A7-9CFC-7F00B4F4742E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2323000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7496AE2F-F2E5-40AF-82BC-E8305BE3966B</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>26000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heptagon Fund</gtr:description><gtr:end>2007-09-02</gtr:end><gtr:fundingOrg>Heptagon Fund</gtr:fundingOrg><gtr:id>1CD0941A-17BD-4B1F-AA82-2025C23CB350</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>817000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>A09A3FF2-0A39-4F75-B70D-B5BA90335E34</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St. Thomas' Charity/Novartis Clinical Trial</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>63245DFC-CDED-4E26-8DCB-75797E973B06</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Guy's and St Thomas' Biomedical Research Centre</gtr:department><gtr:description>Biomedical Research Centre, Programme Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Guy's and St Thomas' NHS Foundation Trust</gtr:fundingOrg><gtr:id>2D1D9284-9FBC-470A-913F-FA82FB0A79AC</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>670000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/EPSRC Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4D5C884A-2D21-4E45-8DC2-3E5B9EBBDA1C</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205428</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>3CAFC2A7-CDD7-4B7D-8B17-3B05E8A19360</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Research Award</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FD03776C-F69E-4A26-8268-C2EF431A8464</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Project Grant</gtr:description><gtr:end>2008-01-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>750C9012-0BE8-40F6-950E-E1FA94E99BBD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Asthma UK Consultation on Basic Asthma Research Strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B117E617-3920-4E13-B12B-B533A223B3F5</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Asthma UK Consultation on Basic Asthma Research Strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B0023988-FEC2-436E-984B-6E8874502DA5</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Crystal structure of IgE-Fc determined at high resolution (1.9 Angstroms); valuable for anti-IgE drug discovery; PDB code 2WQR</gtr:description><gtr:id>C00A7F92-512A-4B3F-904D-DC8291CE2CC8</gtr:id><gtr:impact>This structure has enabled in silico and rational design of anti-IgE inhibitors, which are currently being evaluated.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>High resolution IgE-Fc structure</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=2WQR</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Crystal structure of IgE-Fc. Coordinates deposited in the Protein Data Bank code 2wqr.</gtr:description><gtr:id>24DA0F89-C3F1-4719-B8D3-9878F04FD3F8</gtr:id><gtr:impact>This structure of IgE-Fc revealed the molecule to be acutely bent, and this led to understanding that allosteric approaches to inhibiting IgE activity might be possible.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IgE-Fc crystal structure</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=2WQR</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>X-ray crystal structure at high resolution of IgE-Fc (PDB code 2wqr), and also the structure of the complex with receptor.</gtr:description><gtr:id>704AFFC8-465F-4A6A-9A1F-848866B06078</gtr:id><gtr:impact>The structural data reveal conformational changes that can be targetted in the design of an allosteric inhibitor of the IgE/receptor interaction. A drug discovery programme is in progress, both in-house and as an industrial collaboration.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Structure of IgE-Fc and receptor complex</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=2WQR</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Transgenic mouse model for intervention in allergic disease and for immunotherpy for cancer.</gtr:description><gtr:id>5585D3ED-2888-4F30-B722-782B2FC02B45</gtr:id><gtr:impact>On-going development programme for small molecule inhibitors of IgE/receptor interactions in allergy, and on-going trials of IgE in cancer immunotherapy.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mouse model for allergy and cancer immunotherapy</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Fluorescently labelled versions of IgE-Fc that are sensitive to conformational changes in the IgE molecule. Valuable for screening for small molecules that influence the structure of IgE and that might therefore be leads for IgE inhibitors.</gtr:description><gtr:id>5A1E825E-E00F-4B0D-AFD2-5F1509229C78</gtr:id><gtr:impact>Currently under investigation within our group; publications in preparation; potential IgE small molecule inhibitors.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fluorescently labelled IgE biosensors</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Improved cell lines producing IgE antibodies</gtr:description><gtr:id>9474B5CD-76FD-49DF-B220-6354DA2DF392</gtr:id><gtr:impact>Ongoing trials of IgE for cancer immunotherapy</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cell lines producing recombinant IgE</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89E50D5A-1758-466E-B1D1-27D3DAFE5A83"><gtr:id>89E50D5A-1758-466E-B1D1-27D3DAFE5A83</gtr:id><gtr:title>Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/584f89b9d522deadc9b7bb0cc70c7031"><gtr:id>584f89b9d522deadc9b7bb0cc70c7031</gtr:id><gtr:otherNames>Asokan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CF4DB46-9480-4A80-98A8-3241B8F788D3"><gtr:id>1CF4DB46-9480-4A80-98A8-3241B8F788D3</gtr:id><gtr:title>Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d5b2119e9154040862fe1f15d13a94a"><gtr:id>7d5b2119e9154040862fe1f15d13a94a</gtr:id><gtr:otherNames>Bracher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A1D7589F-DEE6-4257-AE4F-04989372EB17"><gtr:id>A1D7589F-DEE6-4257-AE4F-04989372EB17</gtr:id><gtr:title>The intrinsic flexibility of IgE and its role in binding FcepsilonRI.</gtr:title><gtr:parentPublicationTitle>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5601fc58d8de5584ac2f26c8ee77f053"><gtr:id>5601fc58d8de5584ac2f26c8ee77f053</gtr:id><gtr:otherNames>Harwood NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0753-3322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD8EA7A9-C65B-4841-B0ED-B34DE620965B"><gtr:id>AD8EA7A9-C65B-4841-B0ED-B34DE620965B</gtr:id><gtr:title>Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor Fc?RI.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/912538b3960e48e1db262c7f0859431b"><gtr:id>912538b3960e48e1db262c7f0859431b</gtr:id><gtr:otherNames>Holdom MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/350B66C5-8A7B-403B-90A0-7B1398FA80B3"><gtr:id>350B66C5-8A7B-403B-90A0-7B1398FA80B3</gtr:id><gtr:title>Catalytic folding of the Cepsilon3 domain by its high affinity receptor.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5601fc58d8de5584ac2f26c8ee77f053"><gtr:id>5601fc58d8de5584ac2f26c8ee77f053</gtr:id><gtr:otherNames>Harwood NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/806DB267-D6CC-477B-A3A2-4A2CE7702E7B"><gtr:id>806DB267-D6CC-477B-A3A2-4A2CE7702E7B</gtr:id><gtr:title>Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2049acce0b055e5c624e943097bb52fc"><gtr:id>2049acce0b055e5c624e943097bb52fc</gtr:id><gtr:otherNames>Coker HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3431C3B2-052D-4C3F-8C22-D38A66191630"><gtr:id>3431C3B2-052D-4C3F-8C22-D38A66191630</gtr:id><gtr:title>The structure of human CD23 and its interactions with IgE and CD21.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5edd75b9d7882d8c4d6d26d9f56fc7d2"><gtr:id>5edd75b9d7882d8c4d6d26d9f56fc7d2</gtr:id><gtr:otherNames>Hibbert RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2111325-31FC-4B2B-BB84-6757B00869C3"><gtr:id>C2111325-31FC-4B2B-BB84-6757B00869C3</gtr:id><gtr:title>Soluble CD23 monomers inhibit and oligomers stimulate IGE synthesis in human B cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c7389df9170532df71986f61b6b72f81"><gtr:id>c7389df9170532df71986f61b6b72f81</gtr:id><gtr:otherNames>McCloskey N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38BAC671-2BAF-4E06-9219-04CD9A52C0AC"><gtr:id>38BAC671-2BAF-4E06-9219-04CD9A52C0AC</gtr:id><gtr:title>The allergic march from Staphylococcus aureus superantigens to immunoglobulin E.</gtr:title><gtr:parentPublicationTitle>Chemical immunology and allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d366311edfeaa1ca0c49c81e1c1a6e0a"><gtr:id>d366311edfeaa1ca0c49c81e1c1a6e0a</gtr:id><gtr:otherNames>Gould HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0079-6034</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41AF93D8-9261-4F5A-815F-FC389F0E9EDB"><gtr:id>41AF93D8-9261-4F5A-815F-FC389F0E9EDB</gtr:id><gtr:title>Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c11f0fc7f828a365a5b00dfb947462a"><gtr:id>1c11f0fc7f828a365a5b00dfb947462a</gtr:id><gtr:otherNames>Karagiannis SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C1681D7-D1B5-4220-A70C-36AD8A4122E8"><gtr:id>6C1681D7-D1B5-4220-A70C-36AD8A4122E8</gtr:id><gtr:title>IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c11f0fc7f828a365a5b00dfb947462a"><gtr:id>1c11f0fc7f828a365a5b00dfb947462a</gtr:id><gtr:otherNames>Karagiannis SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3780775F-FF3E-445D-9D3D-568B52DFD323"><gtr:id>3780775F-FF3E-445D-9D3D-568B52DFD323</gtr:id><gtr:title>Ontogeny of human IgE-expressing B cells and plasma cells.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/abff5f3c583fc3f81163ddc836927686"><gtr:id>abff5f3c583fc3f81163ddc836927686</gtr:id><gtr:otherNames>Ramadani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/471F56EB-67EF-46F6-8C35-C56E44F0C303"><gtr:id>471F56EB-67EF-46F6-8C35-C56E44F0C303</gtr:id><gtr:title>The key role of protein flexibility in modulating IgE interactions.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f028e45f967b5d7ce613c7ac722cbe3"><gtr:id>6f028e45f967b5d7ce613c7ac722cbe3</gtr:id><gtr:otherNames>Price NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F71D9879-4122-488C-B2AB-9CC56CA37AD3"><gtr:id>F71D9879-4122-488C-B2AB-9CC56CA37AD3</gtr:id><gtr:title>Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c1ca9da6894e26b6337b69fcd4be667c"><gtr:id>c1ca9da6894e26b6337b69fcd4be667c</gtr:id><gtr:otherNames>Karagiannis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200486</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>